Partial
Needs Correction
Patient Risk:
Moderate
Summary
Several core label-based claims are accurate (indication, brand name, general mechanism, pancreatitis/hypersensitivity warnings, CYP3A4/5 inhibitor dose limit concept). However, multiple statements about dosing, hypoglycemia risk when taken alone, and infection/adverse event frequency are unsupported or potentially contradicted by the provided label excerpts (notably the 1-tablet 5 mg once-daily regimen, lack of hypoglycemia risk with monotherapy, and listing sinusitis as common).
Category Scores
Accurate Statements
Saxagliptin hydrochloride is a small-molecule drug that inhibits dipeptidyl peptidase-4 (DPP-4).
12.1 Mechanism of Action: saxagliptin is a competitive DPP4 inhibitor.
Saxagliptin hydrochloride is sold under the brand name Onglyza.
Drug/Active ingredient(s): ONGLYZA (saxagliptin) tablets (oral; film-coated).
Saxagliptin hydrochloride is used to improve glycemic control in people with type 2 diabetes mellitus.
1.1 Indications and Usage: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Serious adverse events such as pancreatitis can occur with saxagliptin hydrochloride.
5.1 Pancreatitis: postmarketing reports of acute pancreatitis; 6.2 Postmarketing Experience: Acute pancreatitis.
The dose of saxagliptin hydrochloride may be increased to 10 mg if needed and tolerated.
Saxagliptin’s slightly longer half-life can support once-daily dosing.
Unsupported Statements
Saxagliptin hydrochloride boosts insulin release in a glucose-dependent way.
Provided label excerpt describes DPP-4 inhibition and increased incretin concentrations reducing glucose; it does not explicitly state glucose-dependent insulin release or glucagon suppression.
Saxagliptin hydrochloride suppresses glucagon secretion in a glucose-dependent way.
Provided label excerpt does not explicitly state glucagon suppression.
Saxagliptin hydrochloride lowers blood sugar levels.
Label excerpt states reducing fasting and postprandial glucose concentrations, but does not use the specific wording 'lowers blood sugar levels' in the provided sections; treat as generally derivative and not directly supported as phrased.
When taken alone, saxagliptin hydrochloride does not increase the risk of hypoglycemia.
Label excerpt indicates hypoglycemia incidence is increased when used with sulfonylurea or insulin; it does not state absence of increased hypoglycemia risk with monotherapy.
Patients normally take one 5-mg tablet by mouth once daily, with or without food.
Label excerpt provides recommended doses of 2.5 mg or 5 mg once daily regardless of meals, but does not state 'normally take one 5-mg tablet' as the usual regimen.
The dose of saxagliptin hydrochloride may be increased to 10 mg if needed and tolerated.
Provided label excerpt lists doses 2.5 mg and 5 mg once daily; no 10 mg dose is supported in the excerpt.
Common side effects of saxagliptin hydrochloride include mild gastrointestinal upset (nausea and diarrhea).
No nausea/diarrhea 'common' statements appear in the provided label excerpts.
Common side effects of saxagliptin hydrochloride include sinusitis.
No sinusitis 'common' statement appears in the provided label excerpts.
Common side effects of saxagliptin hydrochloride include upper respiratory infections.
No upper respiratory infection 'common' statement appears in the provided label excerpts.
Allergic reactions are rare but monitored with saxagliptin hydrochloride.
Label excerpt confirms postmarketing serious hypersensitivity and warns to discontinue and assess; it does not characterize frequency as 'rare' in the provided portions.
The first-in-class DPP-4 inhibitor was approved in 2009.
No approval year or 'first-in-class' statement appears in the provided label excerpts.
Primary patents covering the active substance, formulation, and route of administration expire between 2023 and 2027 depending on the territory.
Patent/exclusivity details are not present in the provided label excerpts.
Generic versions of saxagliptin are likely to enter the market shortly after the last patent lapses.
Market/patent timeline statements are not present in the provided label excerpts.
Biosimilar equivalents are not applicable because saxagliptin is a small molecule, not a biologic.
Biosimilar applicability statements are not present in the provided label excerpts.
Merck & Co. owns core patents on saxagliptin chemistry and delivery.
Ownership/patent holder information is not present in the provided label excerpts.
Secondary patents cover specific tablet coatings, manufacturing processes, and combination therapy regimens.
Patent scope details are not present in the provided label excerpts.
After the original patents expire, saxagliptin enters the generic market.
Regulatory/market outcome is not present in the provided label excerpts.
After the original patents expire, other manufacturers can produce and sell saxagliptin at a lower cost.
Pricing/production statements are not present in the provided label excerpts.
The exact exclusivity window varies by country but generally ranges from 5 to 7 years after the last patent expiry.
Exclusivity window ranges are not present in the provided label excerpts.
Compared with sitagliptin or linagliptin, saxagliptin has a slightly longer half-life.
No comparative half-life data versus sitagliptin/linagliptin appears in the provided label excerpts.
Saxagliptin’s slightly longer half-life can support once-daily dosing.
No comparative half-life rationale for once-daily dosing appears in the provided label excerpts.
The safety profile of saxagliptin is similar to that of sitagliptin or linagliptin.
No comparative safety profile statement appears in the provided label excerpts.
Head-to-head trials show no clinically significant differences in glycemic control or weight impact between saxagliptin and sitagliptin or linagliptin.
No head-to-head comparative trial results versus sitagliptin/linagliptin appear in the provided label excerpts.
Saxagliptin is metabolized mainly by CYP3A4 and CYP2C8.
Provided label excerpt only addresses strong CYP3A4/5 inhibitors and ketoconazole exposure; it does not mention CYP2C8.
Strong inhibitors or inducers of CYP3A4 and CYP2C8 can alter saxagliptin levels.
Label excerpt specifically addresses strong CYP3A4/5 inhibitors (ketoconazole) and dose limitation; it does not mention CYP2C8 or inducers.
Patients on multiple medications should discuss potential interactions with their healthcare provider.
General counseling statements are not present in the provided label excerpts.
Contradictions
High
AI Statement
The dose of saxagliptin hydrochloride may be increased to 10 mg if needed and tolerated.
Label Reference
2.1 Recommended Dosing: recommended dose is 2.5 mg or 5 mg once daily; no 10 mg option shown in the provided excerpts.
Important Omissions
Renal impairment dosing guidance (e.g., 2.5 mg once daily for moderate/severe renal impairment or ESRD on hemodialysis) and dialysis administration timing.
Importance:
Moderate
For strong CYP3A4/5 inhibitors, the specific dose limitation to 2.5 mg once daily rather than a general interaction statement.
Importance:
Moderate
Tablet handling instruction: tablets must not be split or cut.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
A high-severity dosing contradiction is present (claim of possible increase to 10 mg). Multiple safety-related statements (hypoglycemia risk with monotherapy; specific adverse events listed as 'common') are unsupported and could mislead safety expectations. Label-based hypoglycemia risk applies specifically to combination with sulfonylurea/insulin.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Correction
Primary Issue
Incorrect/unsupported dosing information (10 mg titration claim) and unsupported adverse event frequency statements; hypoglycemia-on-monotherapy claim not supported by provided label excerpts.
Suggested Improvement
Restrict dosing claims to label-supported 2.5 mg or 5 mg once daily and include renal-dose/dialysis instructions and strong CYP3A4/5 inhibitor dose limitation (2.5 mg). Remove or qualify unsupported 'common' adverse events (sinusitis/URI/nausea/diarrhea) and avoid stating hypoglycemia is not increased with monotherapy unless supported in the label excerpt.